Meet the editor

Berend Olivier obtained a Ph.D. in Neurobiology at Groningen University, Netherlands. He worked for twenty-two years at Solvay Pharmaceuticals leading research and development of antidepressants, antipsychotics, anxiolytics, and serenics. He was involved in the research and development of fluvoxamine, a marketed SSSR antidepressant, anxiolytic and anti-OCD medication. During the period from 1999 to 2001, he worked in

New York to start a biotech company, PsychoGenics Inc., developing psychiatric and neurological (genetic) models to screen, find and develop new drugs. From 1992 to 2014 he was a professor of CNS Pharmacology at Utrecht University, Netherlands, performing research on animal models, brain mechanisms, and pharmacology of psychiatric disorders. Since 2014, he has been developing new animal models of male sexual disorders in the hopes of finding new medicines for premature and delayed ejaculation.

## Contents

